Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.

@article{Sandler2009RetrospectiveEO,
  title={Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.},
  author={Alan B. Sandler and Joan Hoff Schiller and Robert J. Gray and Isaiah W. Dimery and Julie Brahmer and Meghna K Samant and Lisa I. Wang and David H. Johnson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 9},
  pages={1405-12}
}
PURPOSE Severe (grade >or= 3) pulmonary hemorrhage (PH) in advanced non-small-cell lung cancer was observed in two prospective, randomized, phase II (N = 99) and phase III (N = 878) trials of bevacizumab plus carboplatin and paclitaxel. Retrospective case-control and cohort analyses were conducted to identify associated radiographic and clinical risk factors for PH. PATIENTS AND METHODS Six patients with PH from the phase II trial, 15 potential PH patients with hemorrhage at any site from the… CONTINUE READING